Biotech Stock for Options Bears to Target Right Now

Crispr Therapeutics (CRSP) is signaling a potential downturn after a recent rally, as the stock approaches its 260-day moving average, a historically bearish indicator. According to Schaeffer's research, similar setups in the past three years have resulted in CRSP averaging an 8% loss one month later 80% of the time. Furthermore, a high call/put ratio over the last two weeks suggests potential headwinds from an unwinding of bullish options positions.

Analysis

Crispr Therapeutics Inc. (CRSP) is exhibiting signs of a potential reversal after a notable June rally, with its shares recently snapping a seven-day winning streak and trading down 0.6% to $42.69. A significant technical indicator suggests further downside: the stock has approached its 260-day moving average after trading substantially below it for an extended period, specifically being within 0.75 of the trendline's 20-day average true range (ATR) after spending at least 80% of the last 10 days and 80% of the last two months below it. Historical data from Schaeffer's Senior Quantitative Analyst Rocky White indicates that following five similar occurrences in the past three years, CRSP experienced an average decline of 8% one month later, with an 80% probability of a negative return. A comparable move from its current price would push CRSP below the critical $40 level, which previously served as a resistance point from mid-April to late last week. Compounding these technical headwinds, options market activity reveals a surge in bullish sentiment, evidenced by a call-to-put volume ratio of 14.50 over the past two weeks across the ISE, CBOE, and PHLX, a level higher than 99% of readings in the past year. An unwinding of these optimistic positions could exert additional downward pressure on the stock. The general sentiment is strongly negative (score -0.75) with CRSP-specific sentiment at -0.85.

Key Decisions for Investors

• Investors should exercise caution with Crispr Therapeutics due to the historically bearish technical signal near its 260-day moving average, which has preceded an average 8% loss one month later in 80% of past similar occurrences.
• The exceptionally high call/put ratio of 14.50 suggests a crowded bullish options trade; an unwinding of this optimism could act as a significant headwind, warranting close monitoring of the $40 support level.
• Consider reviewing existing long positions or exploring hedging strategies given the confluence of bearish technicals, historical performance patterns, and potentially overextended bullish sentiment in the options market.